Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2021

View Archived Issues

China's NMPA accepts Kintor's IND for topical AR degrader GT-20029

FDA authorizes initiation of pivotal phase III study of NE-3107 in AD

A bivalent measles-based COVID-19 vaccine shows antiviral efficacy in vivo and Th1-biased responses

Multivalent nanobodies potently neutralize SARS-CoV-2 and prevent mutational escape

Positive topline data from phase II study of Allocetra in severe and critical COVID-19

Crinetics initiates phase I study of CRN-04777

Preliminary phase I data show safety and immunogenicity of VXA-CoV2-1 oral tablet vaccine

New cannabinoid CB1 and CB2 receptor ligands identified at Canopy Growth Corp.

Cybrexa 3 patents peptide conjugates of microtubule-targeting agents

Novartis discovers AKR1C3-dependent GTPase KRAS inhibitors

California Institute of Technology, Rockefeller University describe anti-HIV vaccine antibodies

Phase Ib data show lack of objective response for CMP-001 plus atezolizumab in NSCLC

RCC-33 reduces tumor volume in mice inoculated with colorectal cancer cells

ABTL-0812 plus paclitaxel and carboplatin result in increased efficacy in NSCLC

ViaCyte begins phase II study of VC01-103 in type 1 diabetes

JADE family of markers has prognostic value in NSCLC

New dengue virus inhibitor shows preclinical promise

CRY1 protein activators allow circadian clock manipulation with light

Roche discloses new monoglyceride lipase inhibitors

Erlotinib plus anlotinib shows promise in EGFR-mutated NSCLC

FDA grants accelerated approval to Tepmetko for metastatic NSCLC with METex14 skipping alterations

Daiichi Sankyo initiates phase II study of patritumab deruxtecan in EGFR-mutated NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...